MEDICINOVA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MEDICINOVA, INC. (MNOV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 150.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 150.00K shares.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 103.00K shares, a 76.05% decline from fiscal 2024.
- MEDICINOVA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 430.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 150.00K shares 10-Q · filed 2026-08-13 | 150.00K shares derived: sum of 3 quarters · filed 2026-08-13 | |
| 2026-03-31 | 150.00K shares 10-Q · filed 2026-05-14 | 150.00K shares derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 103.00K shares 10-K · filed 2026-03-10 | ||
| 2025-09-30 | 103.00K shares 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | 430.11K shares 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |